SLC5A2 and heart failure: Among the various therapeutic approaches, sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a novel and promising class of drugs in the treatment of heart failure with reduced ejection fraction (HFrEF) [20].